Our ongoing and future work involves active trials to reduce Gαq/11-Q209L oncoproteins through Ric-8A inhibition or phorbol ester inhibitory feedback as two new potential strategies to treat GNAQ/11Q209L melanoma. The gene discussed is RIC8A; the disease is melanoma.